Industry News

Cigna "remains as strong as ever," company officials said Wednesday. Indianapolis-based Anthem planned to close on its purchase of Cigna in a $48 billion deal by the end of 2016, but after the U.S. Department of Justice filed a lawsuit to block the sale, that is unlikely to happen."/>
Anthem: Commitment to Buying Cigna As Strong As Ever [The Hartford Courant]
Cytokinetics, Inc. and The ALS Association today announced the continuation and expansion of their partnership in the fight against ALS, including Cytokinetics’ renewal of its Gold Level Sponsorship of the National Walks to Defeat ALS ® and Platinum Level Sponsorship for initiatives led by The ALS Association Golden West Chapter.. “We are proud to continue and scale up our long-standing partnership with The ALS..."/>
Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’ s disease, other central nervous system diseases, pain and various types of cancer, today announced efficacy data through 31 weeks from the ongoing ANAVEX 2-73..."/>
Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016
Neurocrine Biosciences, Inc. announced today that the Company will report its second quarter 2016 results after the Nasdaq market closes on Wednesday, August 3, 2016. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, August 3, 2016 at 5:00 p.m. Eastern Time. Participants can access the live conference call by dialing 888-632-3384 or 785-424-1675..."/>
Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2016 Results
Baxter's Portfolio Contributed to Growth in Second Quarter. Second Quarter GAAP Earnings Per Share Were $2.19; Adjusted Earnings Per Share Were $0.46. DEERFIELD, Ill.- Baxter International Inc. today reported results for the second quarter of 2016, and increased its sales and earnings per share outlook for full-year 2016."/>
Baxter Reports Second Quarter 2016 Results and Raises Financial Outlook for Full-Year 2016
Penumbra System ® for Stroke Revascularization. BOSTON---- Penumbra, Inc., a global interventional therapies company, today announced that the Penumbra 3 D Trial successfully met the primary trial endpoints, demonstrating non-inferiority in both safety and efficacy of the company’ s next-generation stent retriever, Penumbra 3 D Revascularization Device, when used with Penumbra System aspiration devices..."/>
Randomized Penumbra 3D Trial of Next Generation Stent Retriever Meets Primary Endpoints
Prana Biotechnology, presented results obtained from testing PBT2, Prana’ s lead candidate for Huntington and Alzheimer’ s diseases, at the Alzheimer’ s Association International Conference in Toronto, Canada..."/>
Prana Alzheimer's disease data features at world leading conference
MRI Interventions, Inc. today announced that it has effected a 1- for-40 reverse stock split of the shares of its common stock. As previously announced, the reverse stock split is intended to permit the company to meet one of the listing criteria for The Nasdaq Capital Market as a component of the company’ s financing strategy, however there can be no assurance that the company will be able to satisfy all of the listing criteria.. The reverse stock split..."/>
MRI Interventions, Inc. Announces Reverse Stock Split
IDEXX Laboratories, Inc. today announced the availability of Legiolert, the easiest culture method for the confirmed detection of Legionella pneumophila in drinking water. Legionella pneumophila is the most common Legionella species in water and the primary cause of Legionnaires' disease. 1 This month marks the 40th anniversary of the first..."/>
IDEXX Releases Revolutionary Water Test to Aid in the Fight Against Legionnaires' Disease
Diplomat Pharmacy, Inc. announced today that it will release its second quarter 2016 operating results on Tuesday, August 9, 2016 after market close, with a conference call to follow at 5:00p.m. Eastern Time. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 877-201-0168 or 647-788-4901 for international callers, and referencing participant code 46845396 approximately 15 minutes prior to the call."/>
Diplomat to Release Second Quarter Operating Results and Host Conference Call on Tuesday, August 9, 2016 - Diplomat
Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Health Canada has approved the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients living with severe, symptomatic aortic stenosis and at high or greater risk for surgical aortic valve replacement. The SAPIEN 3 valve builds on Edwards' decades of experience..."/>
Edwards Receives Approval For SAPIEN 3 Heart Valve In Canada
Eli Lilly and Co. through a painful period of job cuts and patent expirations while steering toward new products, will retire at the end of the year. Lechleiter will step down as president and CEO of the Indianapolis pharmaceutical giant on Dec. 31. David Ricks, a senior vice president and president of Lilly Bio-Medicines, will take over Jan. 1.."/>
Eli Lilly CEO John Lechleiter to retire [The Indianapolis Star]
Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider with a select therapeutic development pipeline, announces today that as of 5:00 p.m., Eastern Time, on July 27, 2016 it will effect a 1- for-10 reverse stock split of its outstanding common stock, which will be effective for trading purposes as of the commencement of trading on Thursday, July 28, 2016. At the Annual Meeting of..."/>
Caladrius Biosciences Announces 1-for-10 Reverse Split
Advanzeon Solutions, Inc. announced today that its Chairman and CEO, Clark A. Marcus, has rejoined the America’ s Agenda: Health Care For All Board of Directors, effective immediately. America’ s Agenda, a non-profit organization, brings together national and international labor unions, businesses, health care providers, and government leaders who share a common commitment of providing access to affordable, high quality health care for every American."/>
Advanzeon Solutions, Inc. CEO Clark A. Marcus Returns to the Board of America’s Agenda: Health Care for All
INC Research Holdings, Inc., a leading, global Phase I to IV contract research organization, today announced the launch of the Company’ s Vaccine Catalyst Site network as part of its Catalyst program introduced earlier this year to strengthen collaborations with clinical research sites worldwide, ultimately enhancing patient focus and optimizing study delivery to drive improved predictability and increased efficiency for customers."/>
INC Research Extends Catalyst Program with Launch of Vaccine Catalyst Site Network
Onconova Therapeutics, Inc., a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the subscription period for its previously announced rights Offering of units at a subscription price of $4.10 per unit expired on July 26, 2016, and these rights are no longer exercisable.. The results of the oversubscribed Offering and Onconova’ s estimates regarding the..."/>
Onconova Announces Expiration of Oversubscribed Rights Offering
Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider with a select therapeutic development pipeline, announces today that as of 5:00 p.m., Eastern Time, on July 27, 2016 it will effect a 1- for-10 reverse stock split of its outstanding common stock, which will be effective for trading purposes as of the commencement of trading on Thursday, July 28, 2016."/>
Caladrius Biosciences Announces 1-for-10 Reverse Split
Vermillion company, today announced an agreement with Independent Medical Systems, a preferred provider organization based in Dallas, Texas for coverage of ASPiRA LABS' ovarian cancer risk assessment test, OVA1. "We are pleased to announce OVA1 expansion in our home state with a leading PPO network provider," said Valerie Palmieri, President and CEO of Vermillion, Inc. "Our technology helps define appropriate physician..."/>
ASPiRA LABS Expands Coverage for OVA1 in Texas
Boston Scientific Corporation today announced that it has acquired Cosman Medical, Inc., a privately held Burlington, Mass. manufacturer of radiofrequency ablation systems. The Cosman Medical team and products will become part of the Boston Scientific Neuromodulation business, which offers a range of Spinal Cord Stimulator systems to treat patients with chronic pain, and Deep Brain Stimulation systems* for the treatment of..."/>
Boston Scientific Announces Acquisition of Cosman Medical
EndoChoice Holdings, Inc. announced today that it will release its second quarter 2016 financial results on Wednesday, August 3, 2016 after the market closes. EndoChoice will hold a conference call on Wednesday, August 3, 2016 at 4:30 p.m. ET to discuss the results. The dial-in numbers are 328-5344 for domestic callers and 317-5469 for international callers."/>
EndoChoice to Report Second Quarter 2016 Financial Results on August 3, 2016
Bavarian Nordic A/S today announced the initiation of a Phase 1 clinical trial of MVA-BN YF, a new vaccine candidate based on the Company's proprietary MVA-BN platform, designed to protect against yellow fever virus. The study is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. "We are very pleased to see the advancement of this novel vaccine into human studies."/>
Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine
GeoVax Labs, Inc., a biotechnology company developing human vaccines, today provided an update on its Tetravalent Hemorrhagic Fever Vaccine program, including a demonstration that its vaccines produce non-infectious virus-like particles for each of the four virus targets-- Ebola-Zaire, Ebola-Sudan, Marburg, and Lassa. GeoVax's vaccine is based on the Company's novel Modified Vaccinia Ankara VLP platform, which generates noninfectious VLPs."/>
GeoVax Reports Progress With Hemorrhagic Fever Vaccine Program

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology646 Articles
Financials636 Articles
Consumer Discretionary579 Articles
Industrials432 Articles
Health Care381 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at